Here are five recent financial reports from spine-driven device companies.
Alphatec Holdings' Alphatec Spine reported $47.6 million in 3Q revenue, a 6.2 percent increase over the same period last year. The company's revenue growth was driven by the U.S. market, reporting an increase of 8.9 percent. The company re-launched Alphatec Solus during 3Q and introduced three new products.
InVivo Therapeutics, a company focused on finding solutions for spinal cord injury, reported 3Q net income of $3 million. During the third quarter, the company submitted an IDE and plans to begin human clinical study with its proprietary biopolymer scaffolding device for acute spinal cord injury this year, pending FDA approval.
Spine device company Mazor Robotics reported $1.6 million in 3Q sales, which is a slight increase over the same period last year. During 3Q, the company sold three of its Renaissance systems for robotic guidance during spinal surgery.
Spine device company NuVasive reported 3Q revenue of $132.9 million, which was a 10.5 percent increase over the same period last year. Company CEO Alex Lukianov attributed its success to transactions that enhanced its penetration into the lateral lumbar interbody fusion and NeuroVision markets.
For the first time, Synthes' quarterly revenue exceeded $1 billion, an 11 percent increase over last year. The company's success was driven by double-digit growth in the international markets and new product launches in the European market. Net sales in the North American market experienced a 5 percent growth, compared to 17.3 percent and nearly 30 percent in the European and Asian Pacific markets. The company's shareholders recently approved an acquisition bid from Johnson & Johnson.
Related Articles on Spine Devices:
26 Spine Devices Receive FDA 510(k) Clearance in December
14 Spine Device Company Executive Moves in 2011
KSpine Raises $2.5M for Spinal Implant to Treat Scoliosis
Alphatec Holdings' Alphatec Spine reported $47.6 million in 3Q revenue, a 6.2 percent increase over the same period last year. The company's revenue growth was driven by the U.S. market, reporting an increase of 8.9 percent. The company re-launched Alphatec Solus during 3Q and introduced three new products.
InVivo Therapeutics, a company focused on finding solutions for spinal cord injury, reported 3Q net income of $3 million. During the third quarter, the company submitted an IDE and plans to begin human clinical study with its proprietary biopolymer scaffolding device for acute spinal cord injury this year, pending FDA approval.
Spine device company Mazor Robotics reported $1.6 million in 3Q sales, which is a slight increase over the same period last year. During 3Q, the company sold three of its Renaissance systems for robotic guidance during spinal surgery.
Spine device company NuVasive reported 3Q revenue of $132.9 million, which was a 10.5 percent increase over the same period last year. Company CEO Alex Lukianov attributed its success to transactions that enhanced its penetration into the lateral lumbar interbody fusion and NeuroVision markets.
For the first time, Synthes' quarterly revenue exceeded $1 billion, an 11 percent increase over last year. The company's success was driven by double-digit growth in the international markets and new product launches in the European market. Net sales in the North American market experienced a 5 percent growth, compared to 17.3 percent and nearly 30 percent in the European and Asian Pacific markets. The company's shareholders recently approved an acquisition bid from Johnson & Johnson.
Related Articles on Spine Devices:
26 Spine Devices Receive FDA 510(k) Clearance in December
14 Spine Device Company Executive Moves in 2011
KSpine Raises $2.5M for Spinal Implant to Treat Scoliosis